Chunli Medical disclosed its interim report on August 28. In the first half of 2026, it achieved operating revenue of 417 million yuan, down 14.46% year on year. Net profit attributable to shareholders of the listed company was 120 million yuan, up 4.79% year on year. Basic earnings per share were 0.31 yuan. The company plans to distribute a cash dividend of 1.3 yuan, tax included, for every 10 shares. During the reporting period, revenue declined due to the pace of orthopedic centralized procurement implementation and phased market factors at home and abroad. However, the company achieved steady profit growth through measures such as continuously ensuring stable supply of centralized procurement products, optimizing its product and market structure, and strengthening the competitiveness of its core business.
Beijing Chunlizhengda Medical Instruments Co LtdNet profit up 4.79% and dividend declared, despite revenue decline.
